Skip to main content

Telos Corporation Selected as Prime Contractor for the U.S. Navy SeaPort Next Generation Contract

ASHBURN, Va., Jan. 29, 2025 (GLOBE NEWSWIRE) — Telos Corporation (NASDAQ: TLS), a leading provider of cyber, cloud and enterprise security solutions for the world’s most security-conscious organizations, today announced its on-ramp as a prime contractor to the U.S. Navy – SeaPort Next Generation (SeaPort NxG) multiple award, indefinite-delivery/indefinite-quantity (IDIQ) contract. SeaPort NxG serves the Navy Virtual SYSCOM Commanders, including NAVAIR, NAVFAC, NAVSEA, NAVSUP, NAVWAR and ONR, as well as the Military Sealift Command (MSC) and the United States Marine Corps (USMC). SeaPort NxG is the U.S. Navy’s integrated and mandatory approach to contracting for professional support services (PSS). As a prime contractor, Telos will be eligible to bid on task orders until 2028, at which time the Navy will perform a re-compete for...

Continue reading

HealthTab™ and Patients Know Best® Bring Pharmacy-Based Blood Test Results to Millions in UK

VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) today announced its successful integration of HealthTab™ the Company’s cloud-connected, pharmacy-based platform for testing and health data management, with Patients Know Best (PKB), the UK’s leading patient personal health record (PHR). The new partnership enables a seamless connection between real-time diagnostic results from pharmacy point-of-care testing and PKB’s PHR platform, enhancing data accessibility for patients and healthcare providers alike. Supporting HealthTab’s pilot with North East London, an existing PKB customer, this collaboration marks a significant step forward in advancing the government’s shift to community based screening and a more preventative approach...

Continue reading

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Highlights will include overviews of Calidi’s lead programs, such as its CLD-400 systemic platform targeting metastatic cancers, CLD-201 for advanced solid tumors and CLD-101 for high-grade glioma. A live Q&A session with the leadership...

Continue reading

Premier Health Announces Travel Nurse Contingent Labour Master Agreement with Nova Scotia Health Authority

MONTREAL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that its wholly owned subsidiary Canadian Health Care Agency Ltd (CHCA) was retained as service provider to provide travel nurse contingent labour services to the Nova Scotia Health Authority (NSHA). The agreement has a duration of 3 years, positions CHCA as a vendor of reference with NSHA, and covers Registered Nurses, Specialty Registered Nurses and Licensed Practical Nurses roles. The agreement, as most independent labor contract awards are, is for an execution on request contract which purpose is to meet recurring personnel needs, but for which the number, pace, or frequency of service requests are uncertain. “We are pleased to have the opportunity to...

Continue reading

CervoMed to Present at the 8th International Lewy Body Dementia Conference

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB StudySession...

Continue reading

ZJK Industrial Group Hosts Grand Year-End Celebration to Unite Employees and Stakeholders for a Glorious Future

Shenzhen, China, Jan. 29, 2025 (GLOBE NEWSWIRE) — ZJK Industrial Co. Ltd. (NASDAQ: ZJK) (“ZJK Industrial” or the “Company”), a high-tech precision parts and hardware manufacturer for artificial intelligence (AI) infrastructure and smart technologies, today announced that on January 11, 2025, it held a grand year-end celebration party on behalf of ZJK Industrial Group (“Group” or “ZJK Group”). Employees from all the Group’s subsidiaries—Shenzhen Zhongjinke Hardware Products Co., Ltd., Zhongke Precision Components (Guangdong) Co., Ltd., PSM-ZJK Fasteners (Shenzhen) Co., Ltd., and ZJK Vietnam Precision Components Company Limited—joined the event alongside distinguished guests, including shareholders, directors, and representatives from investors, auditing firms, law firms, and major banks. The celebration, held under the theme of...

Continue reading

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune...

Continue reading

The Chefs’ Warehouse to Announce Fourth Quarter and Fiscal Year 2024 Results on February 12, 2025

RIDGEFIELD, Conn., Jan. 29, 2025 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) today announced that the Company intends to release its financial results for the fourth quarter and fiscal year ended December 27, 2024 before the opening of the stock market on Wednesday, February 12, 2025 and host a conference call at 8:30 a.m. ET on Wednesday, February 12, 2025 to review those results. The conference call will be webcast live from the Company’s investor relations website at http://investors.chefswarehouse.com/. An online archive of the webcast will be available on the Company’s investor relations website for 30 days. About The Chefs’ Warehouse The Chefs’ Warehouse, Inc. (http://www.chefswarehouse.com) is a premier distributor of specialty food products in the United States, the Middle East and Canada focused on serving...

Continue reading

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY. To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the...

Continue reading

Carbon Streaming Announces Project Update

TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Carbon Streaming Corporation (Cboe CA: NETZ) (OTCQB: OFSTF) (FSE: M2Q) (“Carbon Streaming” or the “Company”) today provided a project update with respect to the Purchase and Sale Agreement dated as of May 9, 2023, as amended pursuant to that First Amending Agreement, dated as of February 7, 2024 (the “Sheep Creek Stream”), among Carbon Streaming, Mast Reforestation SPV I, LLC (“Mast”) and its parent company DroneSeed Co., d/b/a Mast Reforestation (“Mast Parent Co”). Carbon Streaming has received a Notice of Adverse Impact from Mast and Mast Parent Co under the Sheep Creek Stream Agreement pursuant to which, among other things, Mast advised Carbon Streaming that the Sheep Creek project has experienced significantly higher than expected mortality rates and that the surviving seedlings had...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.